Abstract
A target-specific mAb for the HER2 receptor is trastuzumab, which is used for treatment of breast cancer. This mAb coupled with radionuclides β or α particle emitters are used for radioimmunotherapy. However, radioimmunotherapy with the whole mAb is still limited due to slow pharmacokinetics. This leads to the slow elimination of trastuzumab from the blood and low tumor to blood and tumor to background ratios. To limit this, a small molecule Fab was introduced but the role in HER2 detection by immuno-PET imaging is unknown.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
